期刊
FUTURE ONCOLOGY
卷 5, 期 9, 页码 1477-1486出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FON.09.110
关键词
breast cancer; FIPI; halopemide; inhibitor; lipid signaling; neutrophil chemotaxis; phospholipase D
类别
资金
- NIH [GM071520, GM084251]
Phospholipase D (PLD)1 and PLD2, the classic mammalian members of the PLD superfamily, have been linked over the past three decades to immune cell function and to cell biological processes required by cancer cells for metastasis. However, owing to the lack of effective small-molecule inhibitors, it has not been possible to validate these roles for the PLDs and to explore the possible utility of acute and chronic PLD inhibition in vivo. The first such inhibitors have recently been described and demonstrated to block neutrophil chemotaxis and invasion by breast cancer cells in culture, increasing the prospects for a new class of therapeutics for autoimmune disorders and several types of metastatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据